Treatment of active corticosteroid-resistant graves' orbitopathy.

Purpose: To assess the efficacy of Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, in thyroid eye disease patients refractory to multiple intravenous steroids.

Methods: Prospective interventional nonrandomized study including active GO defined by Clinical Activity Score (CAS) ≥4 patients resistant to previous intravenous steroids treated with Tocilizumab was conducted from February 2010 to September 2012. Snellen visual acuity, Hertel exophthalmometry, CAS evaluation, TSI levels, ocular motility, and side effects were registered at a 4-week interval.